Skip to main content
Journal cover image

1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress

Publication ,  Conference
Catenacci, DV; Strickler, JH; Shitara, K; Nakamura, Y; Janjigian, YY; Barzi, A; Bekaii-Saab, T; Lenz, HJ; Chung, HC; Tabernero, J; Yoshino, T ...
Published in: Annals of Oncology
September 2021

Duke Scholars

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2021

Volume

32

Start / End Page

S1071 / S1072

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Catenacci, D. V., Strickler, J. H., Shitara, K., Nakamura, Y., Janjigian, Y. Y., Barzi, A., … Marshall, J. L. (2021). 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. In Annals of Oncology (Vol. 32, pp. S1071–S1072). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.1543
Catenacci, D. V., J. H. Strickler, K. Shitara, Y. Nakamura, Y. Y. Janjigian, A. Barzi, T. Bekaii-Saab, et al. “1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress.” In Annals of Oncology, 32:S1071–72. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1543.
Catenacci DV, Strickler JH, Shitara K, Nakamura Y, Janjigian YY, Barzi A, et al. 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. In: Annals of Oncology. Elsevier BV; 2021. p. S1071–2.
Catenacci, D. V., et al. “1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S1071–72. Crossref, doi:10.1016/j.annonc.2021.08.1543.
Catenacci DV, Strickler JH, Shitara K, Nakamura Y, Janjigian YY, Barzi A, Bekaii-Saab T, Lenz HJ, Chung HC, Tabernero J, Yoshino T, Siena S, Mayor JG, Palanca-Wessels MC, Xie D, Marshall JL. 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. Annals of Oncology. Elsevier BV; 2021. p. S1071–S1072.
Journal cover image

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2021

Volume

32

Start / End Page

S1071 / S1072

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis